Repare Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
RPTX Nasdaq 8731 https://www.reparerx.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Repare Therapeutics Inc

Repare Therapeutics Announces Phase 1 Data Highlighting Camonsertib in Combination with Radiotherapy Treatment Presented at the ASTRO Annual Meeting - Sep 30th, 2024 8:05 pm
Repare Therapeutics Inc. (NASDAQ:RPTX) is definitely on the radar of institutional investors who own 36% of the company - Sep 27th, 2024 2:13 pm
Repare Therapeutics Announces New Data Underscoring Need for Additional Treatment Solutions for Patients with Metastatic Gynecologic Cancers - Sep 23rd, 2024 11:05 am
Repare Therapeutics to Present Data from Phase 1/2 TRESR Clinical Trial Evaluating Camonsertib Monotherapy in Multiple Advanced Solid Tumors Harboring ATM Loss-of-Function at ESMO Congress 2024 - Sep 13th, 2024 11:00 am
Repare Therapeutics cuts quarter of its workforce and prioritises clinical assets - Aug 29th, 2024 1:33 pm
Repare Therapeutics Inc. (RPTX): A Promising Penny Stock in Canada’s Evolving Economic Landscape - Aug 29th, 2024 9:19 am
Repare Therapeutics Announces Strategic Reprioritization to Focus on Broad Clinical Portfolio - Aug 28th, 2024 8:05 pm
Repare Therapeutics to Participate in Two Upcoming Investor Conferences - Aug 27th, 2024 11:05 am
Repare Therapeutics Inc. (RPTX) Reports Q2 Loss, Lags Revenue Estimates - Aug 6th, 2024 9:50 pm
Repare Therapeutics Provides Business and Clinical Update and Reports Second Quarter 2024 Financial Results - Aug 6th, 2024 8:05 pm
We Think Repare Therapeutics (NASDAQ:RPTX) Needs To Drive Business Growth Carefully - Aug 1st, 2024 2:42 pm
Tango Therapeutics (TNGX) Surges 6.7%: Is This an Indication of Further Gains? - Jul 23rd, 2024 9:24 am
Alberta Enterprise Corporation invests US$7.5 million into Amplitude precision medicine fund - Jul 16th, 2024 1:00 pm
Repare Therapeutics Announces Positive Initial Data at ESMO GI from Phase 1 MINOTAUR Trial Evaluating Lunresertib in Combination with FOLFIRI - Jun 26th, 2024 2:30 pm
Repare Therapeutics Doses First Patient in Camonsertib Monotherapy Non-Small Cell Lung Cancer Expansion of TRESR Clinical Trial - Jun 10th, 2024 11:05 am
Repare (RPTX) Up 14% as Ovarian Cancer Combo Gets Fast Track Tag - Jun 6th, 2024 1:59 pm
Repare Therapeutics Announces Fast Track Designation Granted by the FDA for Lunresertib in Combination with Camonsertib for the Treatment of Platinum-Resistant Ovarian Cancer - Jun 4th, 2024 8:05 pm
Repare Therapeutics to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference - Jun 3rd, 2024 8:05 pm
Repare Therapeutics to Present Initial Phase 1 MINOTAUR Data at ESMO GI Congress 2024 - May 29th, 2024 11:05 am
Need To Know: Analysts Are Much More Bullish On Repare Therapeutics Inc. (NASDAQ:RPTX) - May 12th, 2024 12:02 pm